Aquestive Therapeutics Q4 Revenue Up 9.7% to $13.02M, EPS Widens to -$0.26
Aquestive Therapeutics reported Q4 revenue of $13.02 million, up 9.7% year over year but falling 2.64% short of the $13.37 million consensus. Earnings per share widened to a $0.26 loss versus a $0.19 loss last year, marking a 100% negative surprise, while manufacturing and supply revenue jumped 12.4% to $11.98 million and co-development fees plunged 33.9% to $0.18 million.
1. Quarterly Financial Results
Aquestive Therapeutics posted Q4 revenue of $13.02 million, up 9.7% year over year, missing estimates by 2.64%. EPS loss widened to $0.26 compared with a $0.19 loss in the year-ago quarter, representing a 100% negative surprise to consensus.
2. Segment Breakdown
Manufacture and supply revenue rose 12.4% year over year to $11.98 million, exceeding the $11.4 million estimate; license and royalty revenue reached $0.85 million, up 2.5% but below the $1.82 million projection; co-development and research fees fell 33.9% to $0.18 million versus a $0.55 million target.
3. Stock Performance Outlook
Shares gained 0.5% over the past month while broader benchmarks declined 1.3%. The company holds a neutral analyst rating, suggesting anticipated performance in line with the market in the near term.